Enalapril: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{CMG}} ===Enalapril maleate (Vasotec)=== ===Metoprolol succinate/Hydrochlorothiazide (Dutoprol)=== ==Overvie..." |
No edit summary |
||
| Line 3: | Line 3: | ||
===[[Enalapril maleate]] ([[Vasotec]])=== | ===[[Enalapril maleate]] ([[Vasotec]])=== | ||
===[[Enalapril maleate/Hydrochlorothiazide|Metoprolol succinate/Hydrochlorothiazide]] | ===[[Enalapril maleate/Hydrochlorothiazide|Metoprolol succinate/Hydrochlorothiazide]] === | ||
==Overview== | ==Overview== | ||
Revision as of 13:47, 23 May 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Enalapril maleate (Vasotec)
Metoprolol succinate/Hydrochlorothiazide
Overview
Enalapril is an angiontensin converting enzyme inhibitor that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hyperkalemia, dizziness, increase in serum blood urea nitrogen, increase in serum creatinine, fatigue.
The active substance metoprolol is employed either as enalapril maleate or as enalapril maleate and hydrochlorothiazide.
Category
angiontensin converting enzyme inhibitor, antihypertensive